Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, zonisamide (Zonegran®) cannot be endorsed for use within NHS Wales as adjunctive therapy in the treatment of partial seizures with or without secondary generalisation in adolescents and children aged 6 years and above. |
||
|
||
Medicine details |
||
| Medicine name | zonisamide (Zonegran®) | |
| Formulation | 25 mg capsule, 50 mg capsule, 100 mg capsule | |
| Reference number | 996 | |
| Indication | For use as adjunctive therapy in the treatment of partial seizures with or without secondary generalisation in adolescents and children aged 6 years and above. |
|
| Company | Eisai Ltd | |
| BNF chapter | Central nervous system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 26/02/2014 | |
| Date of issue | 27/02/2014 | |